Titlebook: Lymphomas 1; Including Hodgkin’s John M. Bennett Book 1981 Martinus Nijhoff Publishers, The Hague 1981 Staging.chemotherapy.lymphoma.patho

異端邪說下

認(rèn)識

0927-3042 cology textbooks are generally out of date. Single papers in specialized journals are informative but seldom comprehensive; these are more often preliminary reports on a very limited number of patients. Certain general journals frequently publish good in-depth reviews of cancer topics, and published

Iniquitous

PACK

Functional

,The Role of Radiation Therapy in Malignant Lymphomas, Including Hodgkin’s Disease, in the mid 1960s, the modern conceptions emerged. Before presenting these fundamental principles a brief journey through the annals of history will be undertaken to outline some of the milestones along the road to the present position.

disrupt

,Pathology of Lymphomas, Including Hodgkin’s Disease,astic process, and secondly, in the subclassification of the process when a definite diagnosis of lymphoma has been established. Lymphomas are classified broadly as Hodgkin’s disease and non-Hodgkin lymphomas. While difficulty in subclassification is encountered in both major categories, the problem

Postulate

,Clinical Features and Clinical Evaluation of Hodgkin’s Disease and the Non-Hodgkin’s Lymphomas,r of important similarities. Both Hodgkin’s disease and the non-Hodgkin’s lymphomas commonly present as solitary or generalized lym-phadenopathy. For both Hodgkin’s disease and the non-Hodgkin’s lymphomas, accurate staging — determining the extent of disease — is the cornerstone for rationale therap

溫室

,Radiographic Approach to the Staging of Lymphoma, Including Hodgkin’s Disease,ulted from greater accuracy in the demonstration of sites of involvement using improved diagnostic and staging techniques coupled with new forms of therapy, including intensive megavoltage radiotherapy, combination chemotherapy, and combined modality therapy. The staging and management of the malign

ornithology

參考書目

,Chemotherapy of Hodgkin’s and Non-Hodgkin’s Lymphomas, potentially curative therapy to all newly diagnosed patients with disseminated Hodgkin’s disease and to demonstrate a clear survival advantage for chemotherapy responders in the non-Hodgkin’s lymphomas. However, the management of an individual patient is frequently controversial. The proliferation